Skip to main content

Table 1 Comparison of clinical, histopathological and molecular data according to methylation classes and diagnoses

From: The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of “CNS tumors with BCOR internal tandem duplication”

 

HGNET-BCOR ITD (n = 29)

HGNET-BCOR EP300:BCOR/BCORL1 fusions (n = 3)

GLIOMAS EP300:BCOR fusion (n = 4)

Location

Infratentorial (52%)

Supratentorial (100%)

Supratentorial (100%)

Age

Median age = 3.5 YO (0;22)

Median age = 27 YO (13;72)

Median age = 12 YO (10;18)

Sex

Male (54%)

Male (100%)

Male (66%)

Radiology

Large, well-circumscribed, solid with meningeal attachment; T1 hypointense, T2 hyperintense, low ADC, heterogeneous enhancement

Large, well-circumscribed, solid with meningeal attachment; T1 hypointense, T2 hyperintense, low ADC, heterogeneous enhancement

Limited data: no meningeal attachment, not well circumscribed, T2 hyperintense, mild enhancement

Histopathology

High-grade solid tumor with perivascular pseudorosettes and microcysts

High-grade solid tumor with perivascular pseudorosettes and microcysts

Infiltrative tumor Variable grade (low in 2 cases, high in 2 cases)

Immunohistochemistry

GFAP-/Olig2+/EMA-/Neuronal markers+/BCOR+

GFAP-/Olig2+/EMA-/Neuronal markers+/BCOR-

GFAP+/Olig2+/Neuronal markers-/BCOR+

DNA-methylation class

HGNET-BCOR

HGNET-BCOR

LGG-MYB/MYBL1

Outcome

65% recurrences

Median PFS = 12.5 months 30% dead at the end of follow-up

Median OS = 26 months

0% recurrences

0% dead at the end of follow-up

Median OS = 27 months

100% recurrences

Median PFS = 4.0 months

0% dead at the end of follow-up

Median OS = 7 months

  1. ADC apparent diffusion coefficient, ITD internal tandem duplication, OS overall survival, PFS progression-free survival, YO years-old